Eli Lilly is extending its neuroscience reach into psychedelics by agreeing to acquire AtaiBeckley, a clinical‑stage firm whose leading candidate could rival a blockbuster Johnson & Johnson depression treatment.
Under the deal announced Thursday, Lilly will pay roughly $2.8 billion in cash for AtaiBeckley, with the potential to add up to another $1 billion if the mental‑health medicines hit predefined milestones.
AtaiBeckley’s most advanced asset, BPL‑003, is derived from 5‑MeO‑DMT, a psychedelic that activates serotonin receptors in the brain, a mechanism believed to rebuild synapses and spur new neural growth—an approach distinct from conventional antidepressants. Because gut enzymes rapidly degrade oral 5‑MeO‑DMT, the company engineered BPL‑003 for intranasal delivery.
Psychedelic administration requires clinical monitoring for safety. In April, AtaiBeckley disclosed Phase 2b data showing swift alleviation of depressive symptoms and an average discharge time of 100 minutes after dosing. The effect of a single intranasal dose persisted for three months, and the drug was well tolerated with no serious adverse events. The candidate has now moved into Phase 3 testing for treatment‑resistant depression, defined as insufficient improvement after at least two antidepressant trials.
“Treatment‑resistant depression remains unmet despite multiple prior therapies,” said Carole Ho, executive vice president and president of Lilly Neuroscience, in a prepared statement. “Millions of patients continue to seek relief and urgently need an effective option. Advancing AtaiBeckley’s investigative programs gives us a genuine opportunity to make a difference.”
BPL‑003 could position Lilly as a direct challenger to Johnson & Johnson’s Spravato, an intranasal ketamine‑based depression drug that generated nearly $1.7 billion in revenue last year. Although Spravato is not classified as a psychedelic, it can produce dissociative effects and likewise must be given in a clinical setting.
In a Thursday research note, UBS analyst Michael Yee observed that the approximately two‑hour monitoring requirement for both Spravato and BPL‑003 is feasible for patients. However, AtaiBeckley’s candidate offers longer durability, potentially needing only four to six clinic visits per year versus the 50 or more sessions often required for Spravato. Lilly joins a growing list of large pharma firms venturing into psychedelic medicines; last year AbbVie acquired bretisilocin, a mid‑stage asset from Gilgamesh Pharmaceuticals aimed at major depressive disorder.
AtaiBeckley was created last year via an all‑stock merger of Atai Life Sciences and Beckley Psytech. BPL‑003 originated from Beckley, while Atai contributed VLS‑01, a buccal‑film DMT formulation for treatment‑resistant depression, and EMP‑01, an oral R‑MDMA candidate for social anxiety disorder. Those Atai programs remain in mid‑stage clinical development.
The AtaiBeckley assets will complement Lilly’s existing pipeline, which includes brenipatide—a dual GLP‑1/GIP receptor agonist in late‑stage testing for major depressive disorder and alcohol use disorder. Bolstered by cash from its approved GLP‑1/GIP metabolic drugs, Lilly’s active M&A campaign—this acquisition marks its twelfth deal this year—continues to focus on neuroscience. In March, Lilly agreed to pay $6.3 billion for Centessa Pharmaceuticals, whose lead molecule holds promise for narcolepsy and other sleep disorders.
Lilly’s upfront payment for AtaiBeckley equates to $6.75 in cash per share, a 40 % premium over the stock’s 30‑day average price before the announcement. The company could pay an additional up to $2.50 per share if BPL‑003 and VLS‑01 achieve specified development and regulatory milestones. The transaction remains subject to regulatory clearance and AtaiBeckley shareholder approval, with Lilly expecting to close the deal in the current quarter.
Photo: Richard Drury, Getty Images